Delivery of antihistamines through an inhalation route
First Claim
1. A method of treating allergy symptoms comprising administering a therapeutic amount of an antihistamine drug condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% antihistamine drug degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a method aspect of the present invention, an antihistamine is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antihistamine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antihistamine drug degradation products. In a kit aspect of the present invention, a kit for delivering an antihistamine through an inhalation route is provided which comprises: a) a thin coating of an antihistamine drug composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
31 Claims
-
1. A method of treating allergy symptoms comprising administering a therapeutic amount of an antihistamine drug condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% antihistamine drug degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6)
-
7. A method of treating allergy symptoms comprising administering a therapeutic amount of an azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
21. A method of administering an antihistamine drug to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of an antihistamine drug having less than 5% antihistamine drug degradation products and an MMAD less than 3 microns wherein the peak plasma concentration of the antihistamine drug is achieved in less than 0.1 hours.
-
22. A method of administering azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine having less than 5% azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, loratadine, pyrilamine, hydroxyzine, or promethazine is achieved in less than 0.1 hours.
-
23. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an antihistamine drug composition and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31)
-
Specification